Korean biosimilar company Samsung Bioepis is presenting new data on its copy of Humira (adalimumab), which is branded as Imraldi and Hadlima and also referred t 1 June 2022
At the 2022 annual meeting of the American Society of Clinical Oncology (ASCO 22), Shanghai-based cancer company I-Mab is presenting new Phase I data for uliled 30 May 2022
A new kind of treatment which raises the prospect of an off-the-shelf approach to CAR T-cell therapy has scored an early-stage win, lifting shares in developer 27 May 2022
Budget medicine specialist EQRx (Nasdaq: EQRX), a company focused on delivering innovative medicines at significantly lower prices, will present new data for it 27 May 2022
US biotech major Amgen has promised new data from across its oncology innovative medicines and biosimilars portfolio and pipeline at the American Society of Cli 27 May 2022
The world’s leading cancer conference kicks off in Chicago on Friday 3 June, and for many industry participants, it will be the first time they have attended a 25 May 2022
At the 2022 American Psychiatric Association (APA) annual meeting, Israeli generics giant Teva Pharmaceutical will present new data for Austedo (deutetrabenazin 24 May 2022
At the annual European Congress of Rheumatology (EULAR 2022), presentations will include new data from two Phase III studies of bimekizumab, BE MOBILE 1 and BE 23 May 2022
Full results from the MANDALA Phase III trial have been published by British firms Avillion and AstraZeneca in the New England Journal of Medicine. 16 May 2022
At the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Sanofi is presenting results from a pooled analysis of data for nirsev 11 May 2022
At the annual breast cancer congress of the European Society of Medical Oncology (ESMO), Swiss pharma giant Novartis has announced updated median overall surviv 4 May 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.